Compare BridgeBio Pharma Inc (BBIO) vs Vanguard S&P 500 Growth Index Fund ETF (VOOG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
BridgeBio Pharma Inc vs Vanguard S&P 500 Growth Index Fund ETF — how do they compare? BridgeBio Pharma Inc trades at $84.87 (market cap $16.46B), while Vanguard S&P 500 Growth Index Fund ETF trades at $83.18. Which is the better fit depends on your goals.
| BBIO | VOOG | |
|---|---|---|
Market Cap | $16.46B | — |
Sector | Health | Broad Market / Factor |
52-Week High | $90.17 | $85.11 |
52-Week Low | $44.81 | $65.32 |
Enterprise Value | $18.02B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BridgeBio Pharma (BBIO) trades at $83.08, down 3.27% today, near its 52-week high. The stock shows bullish technical momentum with strong moving averages, while fundamentals reveal rapid revenue growth to $502M in 2025 but persistent losses with a -144.4% net margin. Recent news highlights regulatory approvals for acoramidis and a $1B preferred equity raise to fund launches, driving positive sentiment despite earnings misses.
Outlook remains speculative with high execution risk; analyst consensus is strongly bullish (92% buy) targeting $104.57, but profitability challenges and heavy cash burn require successful pipeline commercialization to justify valuation. Key near-term catalysts include FDA decisions on BBP-418 and encaleret in 2026.
VOOG (Vanguard S&P 500 Growth ETF) trades at $82.02, down 1.55% on the day, with a bullish technical signal from moving averages. The ETF recently completed a 1:6 stock split on April 21, 2026, making shares more accessible. Technical indicators show neutral oscillators but bullish moving average alignment, with support clustered around $82.
The ETF's outlook remains positive given its focus on S&P 500 growth stocks and low 0.07% expense ratio. Key risks include technology sector concentration and market volatility. Recent financial media coverage highlights VOOG's strong long-term performance potential compared to peer growth ETFs.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About BridgeBio Pharma Inc
BridgeBio Pharma Inc is involved in identifying advance transformative medicines to treat patients who suffer from Mendelian diseases, which are diseases that arise from defects in a single gene, and cancers with clear genetic drivers. Its product pipeline categories include Mendelian, Genetic Dermatology, Oncology, and Gene therapy.
Read more on BBIO →About Vanguard S&P 500 Growth Index Fund ETF
VOOG is an index-based ETF that tracks the S&P 500 Growth Index, composed of the growth-oriented companies within the S&P 500. It selects constituents based on three key metrics—sales growth, the ratio of earnings change to price, and momentum—offering a highly liquid and low-cost way to capture the high-performing 'growth slice' of the broader U.S. large-cap market.
Read more on VOOG →
